Publication | Closed Access

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematologyPharmacotherapyMedicineAplastic AnemiaPhase 3